Tag

Novaseq X

All articles tagged with #novaseq x

technology4 hours ago•5 min saved

Illumina outlines 18-month NovaSeq X upgrades to boost quality, throughput and speed

Illumina announced an 18‑month roadmap for the NovaSeq X system featuring a Q70 quality score, a 40% output increase to 35 billion reads, and 30% faster runtimes (14B reads in 20–22 hours). The plan adds staggered starts, new flow cells and DRAGEN software to broaden multiomics, oncology and genetics applications. Rollout will span all NovaSeq X installations (~890 systems) and aims to enable higher-quality data at lower cost, advancing oncology, MRD testing and rare-disease research.

via Illumina|

#genomics #high-throughput-sequencing #illumina

business2 years ago•3 min saved

Illumina's Stock Plummets as Growth Projections Continue to Disappoint

Illumina, a leading DNA-reading company, saw its stock crash after slashing its outlook due to macro pressures impacting the life sciences tools industry. The company expects to ship fewer NovaSeq X instruments than previously anticipated, citing purchasing constraints and lengthened sales cycles. Illumina's stock tumbled 9.3% as a result. Additionally, the company continues to face challenges with its acquisition of Grail, as European regulators have ordered Illumina to divest Grail. Analysts have lowered their price targets on Illumina stock, but still believe in the company's long-term potential in the DNA sequencing market.

via Investor's Business Daily|

#business #dna-sequencing #guidance

business2 years ago•2 min saved

Illumina's cost-cutting strategy to combat shrinking margins.

Illumina plans to cut costs by more than $100 million to improve its shrinking margins, including using its NovaSeq X sequencing system to accelerate genomic discoveries and enabling activities in more cost-effective areas. The company's market value has fallen to roughly $34.5 billion from around $75 billion in August 2021, following its controversial $7.1 billion acquisition of Grail, a cancer test developer, which is the focus of a proxy fight between activist investor Carl Icahn and Illumina.

via CNBC|

#business #cost-cutting #grail